These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34582617)

  • 1. Stem-cell based, machine learning approach for optimizing natural killer cell-based personalized immunotherapy for high-grade ovarian cancer.
    Esmail S; Danter WR
    FEBS J; 2022 Feb; 289(4):985-998. PubMed ID: 34582617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.
    Nersesian S; Glazebrook H; Toulany J; Grantham SR; Boudreau JE
    Front Immunol; 2019; 10():1782. PubMed ID: 31456796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
    Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors.
    Khodayari H; Khodayari S; Ebrahimi E; Hadjilooei F; Vesovic M; Mahmoodzadeh H; Saric T; Stücker W; Van Gool S; Hescheler J; Nayernia K
    Cancer Immunol Immunother; 2021 Dec; 70(12):3369-3395. PubMed ID: 34218295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies.
    Wu Q; Tian R; He X; Liu J; Ou C; Li Y; Fu X
    Front Immunol; 2023; 14():1164408. PubMed ID: 37090728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian cancer treatment and natural killer cell-based immunotherapy.
    Fan Z; Han D; Fan X; Zhao L
    Front Immunol; 2023; 14():1308143. PubMed ID: 38187402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Natural Killer Cells for Tumor Immunotherapy.
    Zhang C; Hu Y; Shi C
    Front Immunol; 2020; 11():60. PubMed ID: 32140153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer.
    Hermanson DL; Bendzick L; Pribyl L; McCullar V; Vogel RI; Miller JS; Geller MA; Kaufman DS
    Stem Cells; 2016 Jan; 34(1):93-101. PubMed ID: 26503833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
    Gaggero S; Witt K; Carlsten M; Mitra S
    Front Immunol; 2020; 11():621225. PubMed ID: 33584718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
    Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
    BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
    Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
    BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
    Ben-Shmuel A; Biber G; Barda-Saad M
    Front Immunol; 2020; 11():275. PubMed ID: 32153582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma.
    Pugh-Toole M; Nicolela AP; Nersesian S; Leung BM; Boudreau JE
    Curr Treat Options Oncol; 2022 Feb; 23(2):210-226. PubMed ID: 35192139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.
    Geller MA; Knorr DA; Hermanson DA; Pribyl L; Bendzick L; McCullar V; Miller JS; Kaufman DS
    Cytotherapy; 2013 Oct; 15(10):1297-306. PubMed ID: 23993303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer.
    Bödder J; Zahan T; van Slooten R; Schreibelt G; de Vries IJM; Flórez-Grau G
    Front Immunol; 2020; 11():631713. PubMed ID: 33679726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells.
    Koh J; Lee SB; Park H; Lee HJ; Cho NH; Kim J
    Biochem Biophys Res Commun; 2012 Oct; 427(2):373-8. PubMed ID: 22995296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.
    Jung D; Baek YS; Lee IJ; Kim KY; Jang H; Hwang S; Jung J; Moon YW; Park KS; Choi YS; An HJ
    J Exp Clin Cancer Res; 2021 Oct; 40(1):333. PubMed ID: 34686187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
    Felices M; Chu S; Kodal B; Bendzick L; Ryan C; Lenvik AJ; Boylan KLM; Wong HC; Skubitz APN; Miller JS; Geller MA
    Gynecol Oncol; 2017 Jun; 145(3):453-461. PubMed ID: 28236454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cell‑based immunotherapy for lung cancer: Challenges and perspectives (Review).
    Zeng Y; Lv X; Du J
    Oncol Rep; 2021 Nov; 46(5):. PubMed ID: 34498710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.
    Kaweme NM; Zhou F
    Front Immunol; 2021; 12():683381. PubMed ID: 34220833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.